Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sirolimus as Therapeutic Approach to Uveitis (SAVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00908466
Recruitment Status : Completed
First Posted : May 25, 2009
Results First Posted : August 20, 2018
Last Update Posted : August 20, 2018
Sponsor:
Collaborator:
MacuSight, Inc.
Information provided by (Responsible Party):
Johns Hopkins University

Tracking Information
First Submitted Date  ICMJE April 30, 2009
First Posted Date  ICMJE May 25, 2009
Results First Submitted Date  ICMJE August 24, 2016
Results First Posted Date  ICMJE August 20, 2018
Last Update Posted Date August 20, 2018
Study Start Date  ICMJE July 2009
Actual Primary Completion Date July 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 4, 2017)
Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH) [ Time Frame: 6 months ]
Vitreous Haze is calculated using a 9 step photographic haze in uveitis patients using fundus photograph
Original Primary Outcome Measures  ICMJE
 (submitted: May 22, 2009)
  • Frequency of uveitis attacks- assessed by vitreous haze, vitreous cells, and anterior chamber cells [ Time Frame: 6 months ]
  • Safety and tolerability of Intravitreal and subconjunctival injections of sirolimus assessed by the frequency and severity of adverse events and serious adverse events that are deemed to be related to sirolimus [ Time Frame: 6 months ]
Change History Complete list of historical versions of study NCT00908466 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: May 22, 2009)
Change From Baseline VA by ETDRS [ Time Frame: 6 and 12 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Sirolimus as Therapeutic Approach to Uveitis
Official Title  ICMJE A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis
Brief Summary The purpose of this study is to find out about the safety and effectiveness of the study drug, sirolimus, in patients with uveitis and to utilize the potential effectiveness of sirolimus, and yet to avoid the potential complications of systemic use of the drug. In this study, the investigators will administer sirolimus either around (subconjunctival injection) or inside the eye (intravitreal injection). Local administration of sirolimus to the eye is not expected to have effects on the rest of the body. Therefore, it may offer a safer way than the current methods used to control the inflammation caused by non-infectious uveitis.
Detailed Description

Uveitis is a condition in which certain parts of your eye become inflamed. The inflammation is usually recurrent. If the inflammation is not treated adequately, permanent damage to the eye and to the vision may occur. The inflammation can be caused by infectious or non infectious causes. The current research is being done to determine the safety and the usefulness of treatment of non-infectious uveitis using a drug called sirolimus.

Current treatment options for uveitis include oral corticosteroids and drugs that weaken the immune system of the body (i.e., immunosuppressant drugs). Treatment using oral corticosteroids, especially for long periods, may cause many undesirable side effects and complications such as high blood sugar, high blood pressure, bone weakness, obesity, stomach ulcers, abnormal hair growth, and increased risks of infection. In addition to that, in some cases, the disease cannot be controlled even with the highest dose of steroids.

Injection of steroids around and inside the eye can be used to control uveitis. However, the inflammation does not always respond to such kind of treatment. The eyes may develop high pressure and cataract with injections of steroids into the eyes or around the eyes.

On the other hand, despite their potential effectiveness, treatment with drugs that weaken the immune system may cause severe side effects. Increased risk of infection is a common side effect of all the immunosuppressant drugs. The immune system protects the body from infections. When the immune system is suppressed, infections are more likely to happen. Some of these infections are potentially dangerous. Because the immune system protects the body against some forms of cancer, immunosuppressant drugs are also associated with a slightly increased risk of cancer. For example, long-term use of immunosuppressant drugs may carry an increased risk of developing skin cancer as a result of the combination of the drugs and exposure to sunlight. The immunosuppressive drugs are very powerful and can cause serious side effects such as high blood pressure, kidney problems, and liver problems. Some side effects may not show up until years after the medicine is used.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Uveitis
  • Intermediate Uveitis
  • Posterior Uveitis
  • Panuveitis
Intervention  ICMJE
  • Drug: Sirolimus (rapamycin)
    Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
    Other Name: Rapamycin, Rapamune, Sirolimus
  • Drug: Sirolimus (rapamycin)
    Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
    Other Name: Rapamycin, Rapamune, Sirolimus
Study Arms  ICMJE
  • Experimental: Intravitreal Injection
    Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
    Intervention: Drug: Sirolimus (rapamycin)
  • Experimental: Subconjunctival Injection
    Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
    Intervention: Drug: Sirolimus (rapamycin)
Publications * Vigil EM, Sepah YJ, Watters AL, Sadiq MA, Ansari M, Bittencourt MG, Ibrahim MA, Do DV, Nguyen QD. Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis. J Ophthalmic Inflamm Infect. 2015 Apr 18;5:13. doi: 10.1186/s12348-015-0044-1. eCollection 2015.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 22, 2009)
30
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE February 2013
Actual Primary Completion Date July 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males and females greater than or equal to 18 years of age;
  2. Able to give informed consent and attend all study visits;
  3. Have diagnosis of uveitis determined by the Investigator to be non infectious;

    • Have active uveitis, defined as having at least 1+ Vitreous Haze and/or at least 1+ Vitreous Cell Count (SUN scale), and:

      • are receiving no other treatment; or,
      • are receiving prednisone ≥10 mg/day (or equivalent dose of another corticosteroid) and/or at least 1 other systemic immunosuppressant; or, b. Have inactive disease, defined as having 0.5+ Vitreous Haze or less and a grade of 0.5+ Vitreous Cell Count or less (SUN scale), and:
      • are receiving prednisone <10 mg/day (or equivalent dose of another corticosteroid) and/or at least 1 other systemic immunosuppressant.
  4. Have posterior, intermediate, or panuveitis; for panuveitis, if an anterior component is present, it must be less than the posterior component;
  5. Sufficient inflammation to require systemic treatment and, based on the Investigator's decision, warrants intravitreal or subconjunctival treatment;
  6. Best-corrected (ETDRS) visual acuity of 20/40 to 20/400 (approximately 70 to 20 letters) in the study eye;
  7. Best- corrected ETDRS visual acuity of 20/400 or better in the fellow eye (approximately 20 letters).

Exclusion Criteria:

  1. Patients with bilateral uveitis who are receiving systemic immunosuppressive therapy (e.g., methotrexate, cyclosporine, cyclophosphamide, chlorambucil, mycophenolate mofetil, tacrolimus, or azathioprine) other than prednisone or other corticosteroids for the treatment of the uveitis, and the uveitis in the fellow eyes, in the opinion of the investigator, cannot be controlled with standard local therapies alone;
  2. Any significant ocular disease that could compromise vision in the study eye. These include, but are not limited to:

    • Diabetic retinopathy: proliferative diabetic retinopathy (PDR) or non-proliferative diabetic retinopathy (NPDR) that compromise the vision.
    • Age-related macular degeneration;
    • Myopic degeneration with active subfoveal choroidal neovascularization.
  3. Any of the following treatments within 90 days prior to Day 0 or anticipated use of any of the following treatments to the study eye:

    • Intravitreal injections (including but not limited to steroids or anti-vascular endothelial growth factors);
    • Posterior subtenon's steroids.
  4. Intraocular surgery within 90 days prior to Day 0 in the study eye;
  5. Capsulotomy within 30 days prior to Day 0 in the study eye;
  6. If the patient has had glaucoma surgery (trabeculectomy or aqueous shunt device), there must be adequate conjunctiva
  7. History of vitreoretinal surgery or scleral buckling
  8. Any ocular surgery (including cataract extraction or capsulotomy) of the study eye anticipated within the first 180 days following Day 0;
  9. Intraocular pressure ≥25 mmHg in the study eye (glaucoma patients maintained on no more than 2 topical medications with intraocular pressure (IOP) <25 mmHg are allowed to participate);
  10. Pupillary dilation inadequate for quality stereoscopic fundus photography in the study eye;
  11. Media opacity that would limit clinical visualization;
  12. Presence of any form of ocular malignancy in the study eye, including choroidal melanoma;
  13. History of herpetic infection in the study eye or adnexa;
  14. Presence of known active or inactive toxoplasmosis in either eye;
  15. Ocular or periocular infection in either eye;
  16. Participation in other investigational drug or device clinical trials within 30 days prior to Day 0, or planning to participate in other investigational drug or device clinical trials within 180 days following Day 0. This includes both ocular and non-ocular clinical trials.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00908466
Other Study ID Numbers  ICMJE NA_00028588
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Johns Hopkins University
Study Sponsor  ICMJE Johns Hopkins University
Collaborators  ICMJE MacuSight, Inc.
Investigators  ICMJE
Principal Investigator: Quan D Nguyen, MD, MSc Johns Hopkins University
PRS Account Johns Hopkins University
Verification Date December 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP